Menu ×


Multiple System Atrophy (MSA) Market Segmentation by Type (Parkinsonian, and Cerebellar); by Diagnosis (Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), Tilt Table Test, and Others) – Global Demand Analysis & Opportunity Outlook 2030

  • Text Size:

Extensive insights into the Growth of Multiple System Atrophy (MSA) Market amidst COVID-19

Before we witness the stabilization of economic growth in Europe and North America, Asia Pacific is estimated to bounce back progressively with countries such as China, India, South Korea and Japan witnessing more opportunities to recover from the losses sustained during COVID-19.

Being the biggest market in Eastern Europe, Russia is estimated to take the lowest hit, offering a sigh of relief to the businesses operating in the country. Whereas, GCC is estimated to observe low investments due to the sliding prices of crude oil.

We evaluate the strategies and commitment of the Giant Players in the market towards creating products and services that customers value and rely on.

In an attempt to control and eliminate the surge of coronavirus cases and meet the demand for required medical devices along with providing efficient medical services, there is a drastic shift of investments from authoritative bodies towards the healthcare sector. Where the aftermath of this pandemic may take years to be measured, Research Nester estimates notable expansion of e-health, gaming, and media and entertainment industries till the whole situation is contained and the plan of action for the recovery process is determined. There is an estimated probability of the growth in businesses going back a year if the condition is controlled in the next 2-3 months.                                                         Request Insights

Read More


  • March 18, 2020- Biohaven Pharmaceutical’s myeloperoxidase (MPO) inhibitor, verdiperstat, received fast track designation from the United States Food and Drug Administration for treating multiple system atrophy or MSA. The drug is aimed at slowing the progression of the disease.

Global Multiple System Atrophy (MSA) Market Highlights 2022 – 2030

The global multiple system atrophy (MSA) market is estimated to garner a sizeable revenue by growing at a notable CAGR over the forecast period, i.e., 2022 – 2030. The growth of the market can be attributed to the growing occurrence of multiple system atrophy across the world, significant shift in people’s lifestyles globally, and rising consumption of alcohol and narcotics. As per the data provided by the Rare Diseases organization, the incidence of multiple system atrophy in the United States alone is 0.6 cases per 100,000 people every year. An estimated 1,900 new cases of the disease occur each year in the country. In addition to these, increasing research and development activities to develop an effective treatment for systemic atrophies and rise in healthcare expenditure in developed and developing nations are also expected to drive growth for the market in the upcoming years. Furthermore, high exposure of people to environmental toxins is projected to offer ample growth opportunities to the market in the near future.

Multiple System Atrophy (MSA) Market GraphThe market is segmented by diagnosis into magnetic resonance imaging (MRI), positron emission tomography (PET), single photon emission computed tomography (SPECT), tilt table test, and others, out of which, the magnetic resonance imaging (MRI) segment is anticipated to hold the largest share in the global multiple system atrophy (MSA) market on account of the high usage of MRI techniques for differentiation of systemic atrophy with Parkinson’s disease, and its usefulness in tracking the progression of multiple system atrophy. Along with this, the segment for tilt table test is also predicted to occupy a significant market share during the forecast period owing to the rising use of this test to document the extent of blood pressure irregularities, which is fundamental for diagnosing systemic atrophies. CLICK TO DOWNLOAD SAMPLE REPORT

Healthcare Expenditure per Capita Graph

According to the statistics by the World Health Organization, the global per capita healthcare expenditure amounted to USD 1,064.741 in the year 2017. The worldwide healthcare expenditure per person grew from USD 864.313 in 2008 to USD 1,110.841 in 2018, where the U.S. is the top country that amounted to healthcare expenditure of USD 10, 623.85 per capita in 2018. As of 2018, the domestic general government healthcare spending in the U.S. was USD 5355.79, which grew from USD 3515.82 in 2008. These are some of the factors responsible for market growth over the past few years. Moreover, as per the projections by the Centers for Medicare & Medicaid Services (CMS), the estimated average annual percent change related to National Health Expenditures (NHE) in the U.S. was 5.2% in 2020 as compared to 2019 (4.5%). Furthermore, the National Health Expenditures are projected to reach USD 6,192.5 Billion in 2028, where the per capita expenditure is estimated to touch USD 17,611 in the same year. These are notable indicators that are anticipated to create lucrative business opportunities in upcoming years.

Global Multiple System Atrophy (MSA) Market Regional Synopsis

On the basis of geographical analysis, the global multiple system atrophy (MSA) market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. The market in the Asia Pacific is estimated to witness noteworthy growth over the forecast period on the back of the increasing number of cases of multiple system atrophy, especially in Japan, high patient pool and growing government initiatives to improve the infrastructure of healthcare in the region. Moreover, the market in North America is expected to gather the largest share during the forecast period, which can be credited to the rising prevalence of neurological disorders, increasing healthcare spending, well established healthcare infrastructure, and strong presence of prominent market players in the region. According to the Centers for Medicare and Medicaid Services, U.S. health care spending grew 4.6 percent in 2019, reaching $3.8 trillion or $11,582 per person. The health spending accounted for 17.7 percent of the country’s total GDP share.

The global multiple system atrophy (MSA) market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC, Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis

Market Segmentation

Our in-depth analysis of the global multiple system atrophy (MSA) market includes the following segments:

By Type

  • Parkinsonian
  • Cerebellar

By Diagnosis

  • Magnetic Resonance Imaging (MRI)
  • Positron Emission Tomography (PET)
  • Single Photon Emission Computed Tomography (SPECT)
  • Tilt Table Test
  • Others

Growth Drivers

  • Growing Occurrence of Multiple System Atrophy Across the World
  • Increasing Research and Development Activities to Develop Effective Treatment for Systemic Atrophies


  • Lack of Awareness about the Disease in Lower Economic Regions

Top Featured Companies Dominating the Market

  • Chelsea Therapeutics International, Ltd.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis 
  • Biohaven Pharmaceuticals, Inc.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • AstraZeneca plc
  • Theravance Biopharma, Inc.
  • Merck & Co.
  • Neuropore Therapies Inc
  • Newron Pharmaceuticals SpA
  • ProMIS Neurosciences Inc
  • Stealth BioTherapeutics Corp


Related Reports

Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2021 Research Nester. All Rights Reserved